References
- Studd J. Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60. Climacteric 2009; 12: 206–209
- Pines A, Sturdee D W, Birkhäuser M H, et al. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007; 10: 181–194
- Anderson G L, Limacher M, Assaf A R, et al. The Women's Health Initiative Steering Committee. Effects of conjugated estrogen on postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
- Reginster J Y. Strontium ranelate: 8 years efficacy on vertebral and non-vertebral fractures in postmenopausal osteoporotic women. Osteoporos Int 2008; 19: S131–S132
- Kanis J A, Johnell O, Black D M, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003; 33: 293–300
- Siris E S, Simon J A, Barton I P, et al. Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int 2008; 19: 681–686
- Rizzoli R, Felsenberg D, Laroche M, et al. Strontium ranelate has a more positive influence than alendronate on distal tibia cortical and trabecular bone microstructure in women with postmenopausal osteoporosis. Osteoporos Int 2008; 19(Suppl 2)S233–S250
- Barrett-Connor E, Mosca L, Collins P. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125–137
- Collins P, Mosca L, Geiger M J, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial. Results of a subgroup analyses by age and other factors. Circulation 2009; 119: 922–930
- Schneider J P. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 2009; 64: 18–23
- Wysowski D K. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360: 89–90
- Lee H Y. Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis. Osteoporos Int 2009; 20: 161–162
- Rossouw J E, Prentice R L, Manson J E, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–1477